Last updated: July 28, 2026
Aubagio (teriflunomide) clinical trials update, market analysis, and sales projection (2026–2031)
Aubagio (teriflunomide) remains marketed as an oral, disease-modifying therapy for relapsing forms of multiple sclerosis (RMS). Publicly disclosed trial activity is dominated by long-running or incremental studies (real-world evidence, safety/extension follow-on work, and comparative/health-economics efforts), while near-term market share dynamics hinge on uptake of newer MS oral agents and infusion therapies, payer steering to lower net cost, and patent-driven competitive timing rather than late-stage pipeline breakthroughs.
What clinical trials has Aubagio (teriflunomide) had recently, and what is the status of ongoing studies?
Recent trial activity: what is typically being updated
Most “clinical trials update” coverage for Aubagio in recent years concentrates on:
- Long-term safety follow-up and continuation/extension cohorts (teriflunomide’s known safety profile supports ongoing monitoring).
- Real-world studies in payer-relevant settings (compliance, persistence, switch rates, and pregnancy-risk management workflows).
- Comparative effectiveness analyses vs other oral RMS DMTs (effect on relapse rates, disability progression proxies, and treatment discontinuation).
How the trial profile affects the market narrative
Because teriflunomide is already established, late-stage randomized program launches are not the primary driver of growth. Instead, trial updates mainly influence:
- Label confidence for safety management in routine practice.
- Evidence used by payers and formulary committees for step edits and prior authorization.
- Clinician switching behavior when new oral agents enter formularies.
Key endpoints that matter for RMS purchasing decisions
For Aubagio, trials and follow-on analyses generally focus on:
- Annualized relapse rate and relapse confirmation.
- Disability progression measures (commonly EDSS-derived endpoints).
- MRI measures (new or enlarging T2 lesions, gadolinium-enhancing lesions) as secondary support for payer reviews.
- Safety endpoints tied to routine monitoring: liver enzymes, hematology changes, infection risk, and teratogenicity mitigation workflows.
Is Aubagio approved for which indications, and how do those approvals constrain or expand market opportunity?
Indication scope
Aubagio is approved for RMS, covering:
- Relapsing-remitting multiple sclerosis (RRMS)
- Active secondary progressive multiple sclerosis (SPMS) in certain jurisdictions, where relapses indicate inflammatory activity
Commercial implications
Indication breadth is stable relative to many MS agents, so growth depends more on:
- Patient selection within RMS.
- Treatment sequence decisions (switch from interferons or glatiramer, start vs fumarates/other orals, or sequence after DMT failure).
- Payer channeling and net pricing.
What is the Orange Book status of Aubagio (teriflunomide), and when does it lose exclusivity?
Orange Book basis for generic entry risk
Aubagio is a branded small-molecule product. Generic entry risk is driven by:
- Patent expiration on active ingredient and key formulations or manufacturing processes.
- Exclusivity periods (if any) tied to the approved indication(s) and FDA regulatory history.
Generic timing framework
The practical generic launch question for business planning is:
- Whether there is an unexpired patent barrier preventing approval of an ANDA for teriflunomide tablets (and whether any Paragraph IV certifications have occurred).
- Whether patent protection is broad enough to cover manufacturing variations or only the marketed strength(s).
Actionable market takeaway
For Aubagio, the generic risk assessment is typically more sensitive to:
- Patent coverage on manufacturing/process claims and specific polymorphs/solid-state characteristics (where applicable).
- Secondary formulation patents that survive base compound expiry.
(No Orange Book listing, expiration dates, or patent numbers are provided in the prompt; a complete exclusivity and generic timing schedule cannot be generated without those records.)
How many patents protect Aubagio (teriflunomide), and what types of patents are most important for litigation and licensing?
Patent categories that most often matter for small-molecule MS brands
For established oral MS DMTs, patent estates usually split into:
- Composition of matter (active ingredient salts/polymorphs)
- Formulation patents (tablet composition, coatings, stability)
- Process patents (manufacturing steps, intermediates)
- Method-of-use patents (less common for some established therapies, more common for specific dosing or subpopulations)
- If relevant, additional patents covering specific dosage regimens or combination regimens
Why this matters for business decisions
- Formulation and process claims can delay “at-risk” generic launches even after base compound expiry if they are still enforceable.
- Method-of-use claims may affect “label carving” strategies and settlement licensing scope.
(No dataset of Aubagio patent numbers and assignees is provided in the prompt; a quantified “how many patents” answer cannot be produced accurately.)
What market does Aubagio serve today, who competes with it, and what is the competitive positioning versus other RMS DMTs?
Therapeutic category and channel
Aubagio competes in RMS DMTs:
- Oral MS therapies: teriflunomide (Aubagio) is an oral option among multiple branded and generic-access drugs.
- Infusion and injectable DMTs: competition is driven by payer tiering, clinical preference, and patient adherence.
Competitive comparison drivers
Aubagio’s uptake is influenced by:
- Efficacy profile relative to other oral agents.
- Safety management procedures, especially liver monitoring and pregnancy risk mitigation.
- Switching friction and required washout workflows.
- Net price and formulary placement.
Where competitive pressure tends to come from
In modern MS formularies, the most pressure often comes from:
- Newer oral agents with convenient dosing and payer-preferred pricing
- High-efficacy infusion/injectable therapies that win early-line access
What is the current market size for teriflunomide/Aubagio, and what growth drivers matter most?
Key revenue drivers
For a mature oral DMT:
- Persistence and discontinuation rates (real-world persistence drives net revenue)
- Switching rates (from older orals/injectables, and away from competing orals)
- Formulary status and payer rebates
- Contracting in large accounts and specialty pharmacy channels
Key headwinds
- Generics and authorized generics for competing agents can shift relative affordability.
- High-efficacy therapies can take share in patients escalated early due to higher baseline disease activity.
- Patent/legal developments for teriflunomide itself determine the horizon for gross margin compression from generic entry.
(No current revenue, units, payer coverage, or regional market shares are provided in the prompt; quantified market size cannot be produced.)
How will Aubagio’s market share evolve from 2026 to 2031, and what scenarios should be modeled?
Scenario structure for planning
For branded RMS orals, a practical planning model uses three scenario variables:
- Formulary trajectory (preferred tier vs non-preferred tier)
- Net pricing pressure (rebates and contracting)
- Generic/authorized generic or biosimilar-like competition risk (for small molecules, “generic entry” is the analog)
Most likely qualitative direction
Given Aubagio maturity:
- Growth through new patient starts typically remains constrained unless a payer shift occurs or safety/efficacy data changes treatment selection behavior.
- Share erosion is usually gradual unless a dominant competitor gains preferential status or triggers step-therapy re-design.
(No patent expiration dates, launch timelines, or revenue baselines are provided; numeric projections cannot be generated without those inputs.)
What clinical evidence supports Aubagio in real-world practice, and how does that influence payer and prescriber decisions?
Real-world endpoints payers use
Even when randomized data is stable, real-world studies can shift contracting by showing:
- Treatment adherence and persistence under typical specialty pharmacy workflows.
- Rates of liver enzyme elevations and time-to-management.
- Discontinuation reasons and switch-to-next-DMT patterns.
Pregnancy and risk mitigation workflow
Teriflunomide requires pregnancy prevention and washout procedures. Evidence that operationalizes these workflows (clinician guidance, patient education programs, and adherence supports) can influence adoption by reducing administrative friction.
What formulations of Aubagio are marketed, and are there formulation-specific IP barriers?
Dosage forms
Aubagio is marketed as oral tablets (strengths historically include 7 mg and 14 mg in multiple jurisdictions).
Formulation IP significance
For tablets, formulation IP typically affects:
- Excipients and manufacturing controls
- Solid-state properties
- Stability and shelf-life parameters
(Without specific Aubagio formulation patent listings, a formulation-level IP barrier map cannot be stated.)
What patent litigation, Paragraph IV challenges, or settlements affect Aubagio market access?
How litigation impacts generic timelines
For small-molecule brands, market impact usually comes from:
- Court-ordered stays after Paragraph IV filing
- Settlement timing that determines launch calendars and “design-around” freedom
Business implication
Even a narrow patent can matter if it blocks the approval pathway or triggers restrictive settlement terms.
(No litigation or Paragraph IV records are provided in the prompt; listing cases and dates would be speculative.)
Regulatory and labeling update question: have there been meaningful FDA label changes for Aubagio that affect demand?
Demand-impacting label elements
Label changes that can move demand include:
- Expansion to additional RMS subpopulations
- Safety contraindication updates
- Pregnancy risk wording and risk management language
- Dosing or washout workflow clarifications
(No FDA labeling update history is included in the prompt; a factual “clinical/regulatory update” cannot be produced.)
Aubagio vs competing teriflunomide/other oral RMS DMTs: how does efficacy, safety, and market positioning compare?
Comparison dimensions that drive formulary decisions
- Convenience and dosing frequency
- Safety monitoring burden (liver labs, CBC, infection risk)
- Washout requirements and pregnancy workflow complexity
- Evidence of relapse reduction and disability progression in RMS populations
- Switching and discontinuation rates in real-world cohorts
Commercial positioning
Aubagio’s commercial profile usually reflects:
- A stable efficacy perception
- Manageable safety with routine labs
- Ongoing payer preference depending on net cost vs alternatives
(No competitor-specific numbers or market-share data are provided; a quantified comparison cannot be compiled.)
Key Takeaways
- Aubagio remains an RMS-focused oral DMT with a mature evidence base; recent “trial updates” are primarily safety monitoring and real-world evidence rather than transformative new efficacy readouts.
- Competitive pressure in RMS formularies is driven more by payer tiering, net pricing, and relative convenience than by major label changes.
- A numeric 2026–2031 sales projection and a quantified exclusivity/generic-risk timeline cannot be produced from the information provided in the prompt because Orange Book status, patent numbers/expiration dates, litigation records, and current revenue baselines are not supplied.
FAQs
- How do teriflunomide washout procedures affect adherence and persistence compared with other oral MS drugs?
- What endpoints in RMS real-world studies most influence payer coverage decisions for Aubagio?
- What are the typical reasons for switching away from Aubagio in routine practice, and how does that change net demand?
- How do formulation-specific manufacturing and solid-state patents affect the timing of generic tablet launches for teriflunomide?
- What settlement patterns in MS small-molecule patent litigation most often determine generic launch dates?
References
(No sources are provided or citable from the prompt.)
